Trial Profile

A First-In-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647263 In Adult Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 6647263 (Primary)
Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Pfizer

Most Recent Events

11 Jul 2017 Status changed from active, no longer recruiting to completed.
02 Jun 2017 Results from part I (n=48) and part II (n=10) of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
22 May 2017 Planned End Date changed from 1 Jun 2017 to 1 May 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com